George F. Steinfels
Geen lopende functies
Profiel
George F.
Steinfels is a professional who has held several positions in different firms.
He was the Chief Executive Officer at Diversa Pty Ltd.
and the Chief Business Officer at Rexahn Pharmaceuticals, Inc. He also worked as a Director at MDNA Life Sciences, Inc. and as a Venture Partner at Endeavour Capital Ltd.
Steinfels holds an MBA from the University of Pennsylvania, an undergraduate degree from The Johns Hopkins University, and graduate and doctorate degrees from the University of Maryland.
Eerdere bekende functies van George F. Steinfels
| Bedrijven | Functie | Einde |
|---|---|---|
MDNA Life Sciences, Inc.
 MDNA Life Sciences, Inc. Medical/Nursing ServicesHealth Services MDNA Life Sciences, Inc. engages in the development of molecular tests based on the mitochondrial genome. It focuses on the development and commercial application of mitochondrial DNA based biomarkers for the early detection of prostate, ovarian and lung cancers, and endometriosis. The company was founded by Mark Birch-Machin, Robert Thayer, and Ryan L. Parr in 2001 and is headquartered in West Palm Beach, FL. | Directeur/Bestuurslid | - |
| DIVERSA LIMITED | President | - |
Endeavour Capital Ltd.
 Endeavour Capital Ltd. Investment ManagersFinance Endeavour Capital Ltd (Endeavour Capital) is a private equity firm founded in 1999 by Neville Jordan. The firm is headquartered Wellington, New Zealand. | Private Equity Investor | - |
| REXAHN PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Opleiding van George F. Steinfels
| The Johns Hopkins University | Undergraduate Degree |
| University of Maryland | Doctorate Degree |
| University of Pennsylvania | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
Diversa Pty Ltd.
 Diversa Pty Ltd. Investment ManagersFinance Diversa Pty Ltd. engages in the provision of investment management and financial services. It operates through Superannuation Services and Trustee Services segments. The Superannuation Services segment provides administration and promotion services to superannuation funds and the issue of group risk products. The Trustee Services segment involves in the third party superannuation trustee services and investment services. The company was founded by Matthew Morgan and Angus Craig on July 03, 1997 and is headquartered in Melbourne, Australia. | Finance |
Endeavour Capital Ltd.
Endeavour Capital Ltd. Investment ManagersFinance Endeavour Capital Ltd (Endeavour Capital) is a private equity firm founded in 1999 by Neville Jordan. The firm is headquartered Wellington, New Zealand. | Finance |
MDNA Life Sciences, Inc.
MDNA Life Sciences, Inc. Medical/Nursing ServicesHealth Services MDNA Life Sciences, Inc. engages in the development of molecular tests based on the mitochondrial genome. It focuses on the development and commercial application of mitochondrial DNA based biomarkers for the early detection of prostate, ovarian and lung cancers, and endometriosis. The company was founded by Mark Birch-Machin, Robert Thayer, and Ryan L. Parr in 2001 and is headquartered in West Palm Beach, FL. | Health Services |
